Japan is a key world market for Leqembi ... Eisai's chief executive, Haruo Naito, said the approval makes Leqembi the first approved anti-amyloid Alzheimer’s treatment shown to reduce the ...

The Food and Drug Administration approved it specifically for patients with mild or early cases of dementia. Leqembi, from Japan's Eisai and its U.S. partner Biogen, is a rare success in a field ...

Last accessed: August 2024.11 Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: August 2024.12 The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi ...

Japan’s LNG strategy reveals the tension between advancing clean energy goals and maintaining reliance on fossil fuels.

Experts also noted the lack of data regarding the long-term effectiveness of Leqembi, made by Japanese drugmaker Eisai. “The reality is that the benefits this first treatment provides are just ...

Experts also noted the lack of data regarding the long-term effectiveness of Leqembi, made by Japanese drugmaker Eisai. “The reality is that the benefits this first treatment provides are just ...

UK Drug Regulator Approves Alzheimer's Drug but Government ... lack of data regarding the long-term effectiveness of Leqembi, made by Japanese drugmaker Eisai. “The reality is that the benefits ...